Please login to the form below

Not currently logged in
Email:
Password:

aducanumab

This page shows the latest aducanumab news and features for those working in and with pharma, biotech and healthcare.

Biogen completes filing for highly-anticipated Alzheimer’s drug

Biogen completes filing for highly-anticipated Alzheimer’s drug

It’s been a rocky road for Biogen’s aducanumab – following disappointing results in March last year, Biogen and partner Eisai said they were pulling the plug on the phase 3 ... be enough to get aducanumab to the finish line, considering the FDA

Latest news

More from news
Approximately 10 fully matching, plus 38 partially matching documents found.

Latest Intelligence

  • Alzheimer’s: the search for a cure Alzheimer’s: the search for a cure

    The preponderance of the data indicates aducanumab doesn’t provide a clinical benefit,’ Skorney wrote in a note to investors. ... If, after receiving input from an advisory committee, the FDA decides to approve aducanumab, it will provide an

  • Great expectations: the urgent need for common purpose in Alzheimer’s disease Great expectations: the urgent need for common purpose in Alzheimer’s disease

    Biogen surprised the world last autumn by announcing a re-evaluation of its latest aducanumab trial and the company is now expected to apply for regulatory approval.

  • Detecting Alzheimer’s ahead of a cure Detecting Alzheimer’s ahead of a cure

    Biogen and Eisai also pulled the plug on their Alzheimer’s drug aducanumab, after advice from an independent data monitoring committee forced them to abandon the phase 3 Abeta-targeting candidate.

  • Where next in Alzheimer’s disease R&D? Where next in Alzheimer’s disease R&D?

    Another crushing blow to hopes came on 21 March, when Biogen and Eisai pulled the plug on their phase 3 Abeta-targeting aducanumab. ... N.B. This article was updated on 21 March 2019 following news of Biogen and Eisai's termination of the aducanumab

  • The good, the bad and the ugly The good, the bad and the ugly

    Biogen also has Aducanumab in the pipeline, which is forecast to generate huge sales in the future; however, it must be noted that it is being developed for the treatment of

More from intelligence
Approximately 1 fully matching, plus 5 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Page & Page

For those who can imagine better, Page & Page is home to meaningful encounters of a marketing, communication and creative kind:...

Latest intelligence

CHECKLIST 04: Let’s make your patient recruitment strategies a success
From how to generate insights to define your audience to drilling down those all-important key messages, our checklist has everything you need to think of, covered....
Multichannel engagement and the need for greater understanding of European markets
By Laurence Olding and Georgina James...
A snapshot of… Exscientia
...

Infographics